Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

Pfizer’s biosimilar of Roche’s blockbuster blood cancer and inflammatory diseases drug rituximab has succeeded in a late-stage trial comparing it with the original drug. The company said the ...

Accessed November 25, 2019. 16 Teva. Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States.

A final approval is expected soon. Subject to approval, the rituximab biosimilar will further contribute to revenues. RDY also markets Hervycta (trastuzumab), a biosimilar of Roche’s Herceptin ...

Dr. Reddy’s launches drug-free migraine management device in Europe DRL_RI is being developed as a biosimilar of MabThera (Rituximab), a cluster of differentiation 20 (CD20) directed cytolytic ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from Egypt suggests.

Objective—The TrialNet Study Group evaluated rituximab, a B-cell–depleting monoclonal antibody, for its effect in new-onset patients with type 1A diabetes. Rituximab decreased the loss of C ...

To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), a China ...

Research shows nearly 20% of patients with pemphigus experience relapse. An additional dose of rituximab in patients with a predictor for relapse reduced the relapse rate (2.6%). Patients with ...